Phase 2/3 trial of maintenance lapatinib for HER1/2-positive metastatic bladder cancer
BISCAY trial for bladder cancer – trial design and its potential impact on clinical practice
Treating advanced/metastatic urothelial carcinoma: recent developments in the BGJ398 clinical trial
Overview of urothelial carcinoma treatment landscape – the promise of immunotherapy
Using checkpoint inhibitors at earlier stages of bladder cancer – the next step in immunotherapy?